Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP930818.RALqx7Jt8LhgXl7k166XgG5Ev9oWkXdULvruvHonbodro130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP930818.RALqx7Jt8LhgXl7k166XgG5Ev9oWkXdULvruvHonbodro130_assertion type Assertion NP930818.RALqx7Jt8LhgXl7k166XgG5Ev9oWkXdULvruvHonbodro130_head.
- NP930818.RALqx7Jt8LhgXl7k166XgG5Ev9oWkXdULvruvHonbodro130_assertion description "[Despite patients with FIP1-like-1-platelet-derived growth factor alpha (FIP1L1-PDGFRA) associated HES (myeloid neoplasms associated with PDGFRA rearrangement) have been shown to respond to low-dose imatinib with a complete and durable hematological and cytogenetic remission, influences of imatinib on clinical manifestations related to hypereosinophilia heart involvement are variable.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP930818.RALqx7Jt8LhgXl7k166XgG5Ev9oWkXdULvruvHonbodro130_provenance.
- NP930818.RALqx7Jt8LhgXl7k166XgG5Ev9oWkXdULvruvHonbodro130_assertion evidence source_evidence_literature NP930818.RALqx7Jt8LhgXl7k166XgG5Ev9oWkXdULvruvHonbodro130_provenance.
- NP930818.RALqx7Jt8LhgXl7k166XgG5Ev9oWkXdULvruvHonbodro130_assertion SIO_000772 19096755 NP930818.RALqx7Jt8LhgXl7k166XgG5Ev9oWkXdULvruvHonbodro130_provenance.
- NP930818.RALqx7Jt8LhgXl7k166XgG5Ev9oWkXdULvruvHonbodro130_assertion wasDerivedFrom befree-20140225 NP930818.RALqx7Jt8LhgXl7k166XgG5Ev9oWkXdULvruvHonbodro130_provenance.
- NP930818.RALqx7Jt8LhgXl7k166XgG5Ev9oWkXdULvruvHonbodro130_assertion wasGeneratedBy ECO_0000203 NP930818.RALqx7Jt8LhgXl7k166XgG5Ev9oWkXdULvruvHonbodro130_provenance.